Boston Scientific Announces Agreement to Acquire Cortex, Inc.

Core Viewpoint - Boston Scientific Corporation has announced a definitive agreement to acquire Cortex, Inc., enhancing its electrophysiology portfolio with a new diagnostic mapping solution aimed at improving treatment for complex atrial fibrillation (AF) cases, which affects nearly 38 million people globally [1][2]. Group 1: Acquisition Details - The acquisition of Cortex is expected to complement Boston Scientific's existing electrophysiology offerings by providing a differentiated cardiac mapping solution for complex AF cases [2]. - The OptiMap™ System developed by Cortex utilizes a basket catheter and proprietary algorithm to identify potential active AF sources, allowing for a more individualized ablation strategy [1][2]. - The transaction is anticipated to close in the first half of 2025, subject to customary closing conditions, and is expected to have an immaterial impact on adjusted earnings per share in 2025 [3]. Group 2: Clinical Evidence and Technology - Cortex's OptiMap System received FDA 510(k) clearance in 2023 and has shown promising results in clinical trials, including a 51% improvement in freedom from AF one year post-ablation compared to conventional therapies [2]. - A global clinical trial named RESOLVE-AF has been initiated to further evaluate the effectiveness of the OptiMap System in identifying extra-pulmonary vein sources [2]. Group 3: Company Vision and Future Plans - The CEO of Cortex expressed that joining Boston Scientific will enable further development of their technology, which has the potential to transform AF treatment globally [3]. - Boston Scientific aims to advance the OptiMap technology and generate future clinical evidence to make it accessible to physicians and patients worldwide [2].